Updated on 29 April 2014
Dr Gianella-Borradori has responsibility for all clinical activity in the US and participates in a leadership role on scientific and translational committees in Japan at the parent company
Singapore: Chugai Pharma USA, Berkeley Heights, NJ a wholly owned subsidiary of Chugai Pharmaceutical, Tokyo, Japan, member of the Roche Group has announced the appointment of Athos Gianella-Borradori, MD as Chief Medical Officer of CPUSA.
Dr Gianella-Borradori is an experienced pediatric hematologist-oncologist and executive with more than 20 years of international drug research and development experience, focusing on translational research and clinical development of novel therapeutic agents.
He has held senior positions in research and development at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom), Merck Serono (Switzerland), and Clavis Pharma (Norway).
Dr Gianella-Borradori earned his medical degree at the University of Bern (Switzerland). He is board certified in pediatric hematology and pediatric oncology, and practiced for several years at several university hospitals in Switzerland and US.
Dr Gianella-Borradori has responsibility for all clinical activity in the US and participates in a leadership role on scientific and translational committees in Japan at the parent company. He represents Chugai in relationships with the US Food and Drug Administration (FDA), academia, clinical investigators and patient communities, and is responsible for increasing the awareness of Chugai's impressive achievements in discovering and commercializing innovative pharmaceuticals to facilitate its expanding clinical activity in the US.